Brian Rini, MD, FASCO

Experts share patient-centered strategies for first-line clear cell renal cancer, balancing biology, toxicity, breaks, and emerging trial data.

Kidney cancer treatment shifts toward combo regimens, but missing biomarkers raise overtreatment concerns—experts weigh smarter patient selection.

Oncologists weigh FDA approvals, trial data, and real‑world experience to adopt new renal cancer therapies—nimbly, patient by patient.

Clinicians weigh tolerability against slight tumor growth, using patient-shared scan review and calling for AI volumetric imaging to avoid premature therapy switches.

Clinicians balance cancer control and tolerability by accepting minimal scan “drift,” using qualitative review, and advocating AI volumetric imaging over outdated RECIST.

Experts debate “depth of response” in kidney cancer, warning percentage shrinkage is subjective and variable, while deeper responses generally signal better outcomes.

Learn how clinicians tailor VEGF‑TKI immunotherapy dosing to control cancer fast, curb toxicity, and protect long‑term quality of life.

Why triplet immunotherapy plus VEGF TKI disappoints in kidney cancer—and how symptoms and tumor burden steer first-line TKI–IO choices.

ASCO highlights HIF inhibitors in kidney cancer, showing durable control and strong tolerability as trials test monotherapy vs combination strategies.

Learn how experts tailor kidney cancer first-line therapy—IO-TKI for rapid control, dual immunotherapy for low-burden or sarcomatoid disease.

Why first-line cancer therapy matters: experts weigh proven immunotherapy doublets vs experimental trials, and how tumor biology guides choices.

In this segment, Dr. Brian Rini discusses the heterogeneity of tumor biology in advanced renal cell carcinoma and its implications for clinical decision-making.

In this opening segment, Dr. Thomas Powles sets the stage for a discussion on advanced renal cell carcinoma, emphasizing the critical role of first-line treatment decisions in shaping patient outcomes.